BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10362138)

  • 1. Binding characteristics and tumor targeting of a covalently linked divalent CC49 single-chain antibody.
    Beresford GW; Pavlinkova G; Booth BJ; Batra SK; Colcher D
    Int J Cancer; 1999 Jun; 81(6):911-7. PubMed ID: 10362138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Divalent forms of CC49 single-chain antibody constructs in Pichia pastoris: expression, purification, and characterization.
    Goel A; Beresford GW; Colcher D; Pavlinkova G; Booth BJ; Baranowska-Kortylewicz J; Batra SK
    J Biochem; 2000 May; 127(5):829-36. PubMed ID: 10788792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.
    Chauhan SC; Jain M; Moore ED; Wittel UA; Li J; Gwilt PR; Colcher D; Batra SK
    Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):264-73. PubMed ID: 15791435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts.
    Pavlinkova G; Beresford GW; Booth BJ; Batra SK; Colcher D
    J Nucl Med; 1999 Sep; 40(9):1536-46. PubMed ID: 10492377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs.
    Wittel UA; Jain M; Goel A; Chauhan SC; Colcher D; Batra SK
    Nucl Med Biol; 2005 Feb; 32(2):157-64. PubMed ID: 15721761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and biodistribution of a light-chain-shuffled CC49 single-chain Fv antibody construct.
    Pavlinkova G; Colcher D; Booth BJ; Goel A; Batra SK
    Cancer Immunol Immunother; 2000 Jul; 49(4-5):267-75. PubMed ID: 10941910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application.
    Goel A; Colcher D; Baranowska-Kortylewicz J; Augustine S; Booth BJ; Pavlinkova G; Batra SK
    Cancer Res; 2000 Dec; 60(24):6964-71. PubMed ID: 11156397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma.
    Goel A; Baranowska-Kortylewicz J; Hinrichs SH; Wisecarver J; Pavlinkova G; Augustine S; Colcher D; Booth BJ; Batra SK
    J Nucl Med; 2001 Oct; 42(10):1519-27. PubMed ID: 11585867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct.
    Pavlinkova G; Booth BJ; Batra SK; Colcher D
    Clin Cancer Res; 1999 Sep; 5(9):2613-9. PubMed ID: 10499640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction and purification of a covalently linked divalent tandem single-chain Fv antibody against placental alkaline phosphatase.
    Sheikholvaezin A; Eriksson D; Riklund K; Stigbrand T
    Hybridoma (Larchmt); 2006 Oct; 25(5):255-63. PubMed ID: 17044780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49.
    Milenic DE; Yokota T; Filpula DR; Finkelman MA; Dodd SW; Wood JF; Whitlow M; Snoy P; Schlom J
    Cancer Res; 1991 Dec; 51(23 Pt 1):6363-71. PubMed ID: 1933899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins.
    Slavin-Chiorini DC; Kashmiri SV; Schlom J; Calvo B; Shu LM; Schott ME; Milenic DE; Snoy P; Carrasquillo J; Anderson K
    Cancer Res; 1995 Dec; 55(23 Suppl):5957s-5967s. PubMed ID: 7493377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-chain antibodies in pancreatic cancer.
    Colcher D; Pavlinkova G; Beresford G; Booth BJ; Batra SK
    Ann N Y Acad Sci; 1999 Jun; 880():263-80. PubMed ID: 10415872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
    Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
    Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential metabolic patterns of iodinated versus radiometal chelated anticarcinoma single-chain Fv molecules.
    Schott ME; Milenic DE; Yokota T; Whitlow M; Wood JF; Fordyce WA; Cheng RC; Schlom J
    Cancer Res; 1992 Nov; 52(22):6413-7. PubMed ID: 1423290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv.
    Whitlow M; Filpula D; Rollence ML; Feng SL; Wood JF
    Protein Eng; 1994 Aug; 7(8):1017-26. PubMed ID: 7809028
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.